![Cureus | CD30-Positive Anaplastic Variant of Diffuse Large B-cell Lymphoma: Frequency and Association With Clinicopathological Parameters | Article Cureus | CD30-Positive Anaplastic Variant of Diffuse Large B-cell Lymphoma: Frequency and Association With Clinicopathological Parameters | Article](https://assets.cureus.com/uploads/figure/file/186591/lightbox_24af74e0651111eb9fead96f8fa8523f-fig-1-sharp.png)
Cureus | CD30-Positive Anaplastic Variant of Diffuse Large B-cell Lymphoma: Frequency and Association With Clinicopathological Parameters | Article
![CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL). | Semantic Scholar CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL). | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/13a0056605911a2c6baa2183959798f32efb2db4/4-Table4-1.png)
CD30, CD15, CD50, and PAX5 Expressions as Diagnostic Markers for Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL). | Semantic Scholar
![Case 23. Arthropod reaction with CD30 positive infiltrate and ulceration mimicking CD30 lymphoproliferative disorder | SpringerLink Case 23. Arthropod reaction with CD30 positive infiltrate and ulceration mimicking CD30 lymphoproliferative disorder | SpringerLink](https://media.springernature.com/lw685/springer-static/image/chp%3A10.1007%2F978-3-030-59129-8_23/MediaObjects/489368_1_En_23_Figa_HTML.jpg)
Case 23. Arthropod reaction with CD30 positive infiltrate and ulceration mimicking CD30 lymphoproliferative disorder | SpringerLink
![Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30− Tumors: Molecular Therapy Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30− Tumors: Molecular Therapy](https://www.cell.com/cms/attachment/49e83253-7178-4d71-94f8-6510060460bf/fx1_lrg.jpg)
Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30− Tumors: Molecular Therapy
![Low CD30 Expression in Non-Hodgkin's Lymphoma Patients Does Not Predict Low Response to Brentuximab Vedotin – Consult QD Low CD30 Expression in Non-Hodgkin's Lymphoma Patients Does Not Predict Low Response to Brentuximab Vedotin – Consult QD](https://consultqd.clevelandclinic.org/wp-content/uploads/sites/2/2019/05/650x450-CD3-40x-300x200.jpg)
Low CD30 Expression in Non-Hodgkin's Lymphoma Patients Does Not Predict Low Response to Brentuximab Vedotin – Consult QD
![A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb | Cancer Gene Therapy A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb | Cancer Gene Therapy](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41417-021-00295-8/MediaObjects/41417_2021_295_Fig1_HTML.png)
A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb | Cancer Gene Therapy
![CD30 / TNFRSF8 (Hodgkin & Reed-Sternberg Cell Marker) Antibody - Culture Supernatant - Mouse Monoclonal Antibody [Clone Ber-H2 ] IHC, IF, FC - Buy Now! |Abcepta CD30 / TNFRSF8 (Hodgkin & Reed-Sternberg Cell Marker) Antibody - Culture Supernatant - Mouse Monoclonal Antibody [Clone Ber-H2 ] IHC, IF, FC - Buy Now! |Abcepta](https://www.abcepta.com/assets/uploads/products/201512/AH12687_IHC_1.jpg)